Long-Term Outcomes and Treatment Guidelines in DLBCL Management

Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse large B-cell lymphoma (DLBCL) treatment, offering insights on how to interpret and apply these recommendations in various patient scenarios.

EP: 1.Advances in DLBCL Management: Long-Term Treatment Outcomes

Now Viewing

EP: 2.Long-Term Outcomes and Treatment Guidelines in DLBCL Management

Video content above is prompted by the following:

• Please explain how the 5-year outcomes have impacted polatuzumab’s position in current NCCN guidelines for DLBCL treatment.
  • How do you interpret and apply these guideline recommendations across patient scenarios?

Recent Videos